

# Contents

Contributors

xiii

|                                                                                                           |           |
|-----------------------------------------------------------------------------------------------------------|-----------|
| <b>1. Clinical features of dystonia and the science of classification</b>                                 | <b>1</b>  |
| Alberto Albanese                                                                                          |           |
| 1. Early observations                                                                                     | 1         |
| 2. Phenomenology                                                                                          | 2         |
| 2.1 Tremor in dystonia                                                                                    | 4         |
| 2.2 The spectrum of dystonia                                                                              | 9         |
| 3. Motor features                                                                                         | 10        |
| 3.1 Core features                                                                                         | 10        |
| 3.2 Additional features                                                                                   | 11        |
| 4. Diagnosis                                                                                              | 12        |
| 5. Classification                                                                                         | 13        |
| 6. Current status and beyond                                                                              | 16        |
| References                                                                                                | 17        |
| <b>2. What can epidemiological studies teach on the pathophysiology of adult-onset isolated dystonia?</b> | <b>21</b> |
| Davide Martino                                                                                            |           |
| 1. Introduction                                                                                           | 22        |
| 2. Studies of birth sex in AOID: Suggestions for pathophysiology                                          | 23        |
| 3. How does age affect phenotype and natural history of AOID?                                             | 26        |
| 4. Extra-genetic risk factors and mechanisms of AOID                                                      | 30        |
| 4.1 Physical trauma                                                                                       | 30        |
| 4.2 Repetitive activities                                                                                 | 35        |
| 4.3 Geographic variations                                                                                 | 36        |
| 4.4 Lifestyle and medical comorbidities                                                                   | 40        |
| 5. Clinical and epidemiological studies of non-motor symptoms in AOID: Implications for pathophysiology   | 43        |
| 6. Brain-wide mechanisms and network dysfunction: Supporting evidence from epidemiologic data             | 46        |
| 6.1 Defective inhibitory mechanisms                                                                       | 46        |
| 6.2 Altered synaptic plasticity and imbalance in the cortico-basal ganglia circuitry                      | 47        |

|                                                                                                      |            |
|------------------------------------------------------------------------------------------------------|------------|
| 6.3 Dysfunctional connectivity beyond the cortico-basal ganglia circuitry                            | 48         |
| 7. Form-specific mechanisms: Supporting evidence from epidemiologic data                             | 49         |
| 7.1 Cervical dystonia                                                                                | 49         |
| 7.2 Blepharospasm                                                                                    | 50         |
| 7.3 Upper limb dystonia                                                                              | 51         |
| 8. Where to go next investigating risk- and course-modifying factors of dystonia? Conclusive remarks | 52         |
| 8.1 "Non-modifiable" factors                                                                         | 52         |
| 8.2 "Modifiable" factors                                                                             | 53         |
| References                                                                                           | 54         |
| <b>3. Dystonia genes and their biological pathways</b>                                               | <b>61</b>  |
| Alessio Di Fonzo, H. A. Jinnah, and Michael Zech                                                     |            |
| 1. Introduction                                                                                      | 62         |
| 1.1 Dopamine signaling abnormalities                                                                 | 64         |
| 1.2 Heavy metal accumulation and brain calcifications                                                | 70         |
| 1.3 Defects of the nuclear envelope and stress response                                              | 73         |
| 1.4 Perturbation of gene-expression control in the nucleus                                           | 76         |
| 1.5 Mitochondrial and energy homeostasis dysfunction                                                 | 79         |
| 1.6 Cellular trafficking alterations with lysosomal-autophagosomal pathology                         | 82         |
| 1.7 Calcium abnormalities and mutant ion channels                                                    | 84         |
| 1.8 Other established and newly emerging mechanisms                                                  | 87         |
| 2. Concluding remarks and future perspectives                                                        | 90         |
| 2.1 Dystonia molecular pathways—Lumping or splitting?                                                | 90         |
| 2.2 Unmet needs and strategies to address them                                                       | 91         |
| References                                                                                           | 92         |
| <b>4. The functional anatomy of dystonia: Recent developments</b>                                    | <b>105</b> |
| Daniel T. Corp, Jordan Morrison-Ham, H. A. Jinnah, and Juho Joutsa                                   |            |
| 1. Introduction                                                                                      | 106        |
| 2. Neuroimaging in idiopathic dystonia                                                               | 106        |
| 2.1 Structural magnetic resonance imaging                                                            | 107        |
| 2.2 Functional magnetic resonance imaging                                                            | 109        |
| 2.3 Molecular neuroimaging                                                                           | 110        |
| 2.4 Summary of neuroimaging in idiopathic dystonia                                                   | 112        |
| 3. Lesion studies                                                                                    | 113        |

|                                                                                                         |                |
|---------------------------------------------------------------------------------------------------------|----------------|
| 3.1 Traditional lesion studies in dystonia                                                              | 113            |
| 3.2 Lesion network mapping in dystonia                                                                  | 118            |
| 4. Animal studies in dystonia                                                                           | 120            |
| 5. Pathways of dystonia                                                                                 | 122            |
| 6. Future directions                                                                                    | 124            |
| 7. Conclusions                                                                                          | 126            |
| Acknowledgements                                                                                        | 127            |
| References                                                                                              | 127            |
| <br><b>5. Physiology of dystonia: Human studies</b>                                                     | <br><b>137</b> |
| Peter Fischer, Dan Piña-Fuentes, Panagiotis Kassavetis, and Anna Sadnicka                               |                |
| 1. Introduction                                                                                         | 138            |
| 2. Inhibition                                                                                           | 138            |
| 3. Plasticity                                                                                           | 142            |
| 4. Limitations of inhibition and plasticity hypothesis                                                  | 144            |
| 5. Peripheral contributions and disrupted sensorimotor integration                                      | 146            |
| 6. Oscillations in dystonia                                                                             | 149            |
| 6.1 Low-frequency oscillations in dystonia                                                              | 149            |
| 6.2 The effect of DBS on LF-oscillations                                                                | 150            |
| 6.3 Significance of prominent LF oscillations                                                           | 151            |
| 6.4 Clinical implications of LF-oscillations in dystonia                                                | 152            |
| 6.5 Other sources of oscillations in dystonia and oscillations in other frequency bands                 | 153            |
| 7. Conclusions                                                                                          | 153            |
| References                                                                                              | 154            |
| <br><b>6. Physiology of Dystonia: Animal Studies</b>                                                    | <br><b>163</b> |
| Alejandro G. Rey Hipolito, Meike E. van der Heijden, and Roy V. Sillitoe                                |                |
| 1. Introduction                                                                                         | 164            |
| 2. Genetic mouse models with mutations in dystonia-associated genes that are affected in human patients | 166            |
| 2.1 DYT1 ( <i>TOR1A</i> )                                                                               | 166            |
| 2.2 DYT5a ( <i>GCH1</i> )                                                                               | 172            |
| 2.3 DYT5b ( <i>TH</i> )                                                                                 | 172            |
| 2.4 DYT6 ( <i>THAP1</i> )                                                                               | 173            |
| 2.5 DYT11 ( <i>SGCE</i> )                                                                               | 174            |
| 2.6 DYT12 ( <i>ATP1A3</i> )                                                                             | 175            |

|           |                                                                                                 |            |
|-----------|-------------------------------------------------------------------------------------------------|------------|
| 2.7       | DT25 ( <i>GNAL</i> )                                                                            | 176        |
| 2.8       | <i>FGF14</i>                                                                                    | 177        |
| 2.9       | Manganese transporter genes ( <i>SLC30A10</i> and <i>SLC39A14</i> )                             | 178        |
| 2.10      | <i>TSPOAP1</i>                                                                                  | 179        |
| 2.11      | <i>SECISBP2</i>                                                                                 | 179        |
| 3.        | Spontaneous genetic models with dystonic movements                                              | 180        |
| 3.1       | <i>BTBR</i> $T^+$ <i>Itpr3<sup>tf</sup>/J</i> ( <i>BTBR</i> )                                   | 180        |
| 3.2       | <i>Cacna1a</i> mutations (including <i>tottering</i> and <i>leaner</i> mice)                    | 181        |
| 3.3       | <i>dt</i> Rat ( <i>Atcay</i> )                                                                  | 185        |
| 3.4       | <i>Dt<sup>sz</sup></i> hamster                                                                  | 187        |
| 3.5       | Dystonia musculorum ( <i>Bpag1</i> )                                                            | 188        |
| 3.6       | <i>Lamb1</i>                                                                                    | 190        |
| 3.7       | <i>Scn8a</i>                                                                                    | 190        |
| 3.8       | <i>Waddles</i> mouse ( <i>Car8</i> )                                                            | 191        |
| 4.        | Neural circuit manipulations causing dystonia                                                   | 192        |
| 4.1       | Agranular mice ( <i>En1<sup>Cre</sup></i> ; <i>Atoh1<sup>flx/flx</sup></i> )                    | 192        |
| 4.2       | Cerebellar serotonergic hyperactivity (virus induced)                                           | 193        |
| 4.3       | <i>Gy7</i>                                                                                      | 193        |
| 4.4       | Olivocerebellar silencing ( <i>Ptf1a<sup>Cre</sup></i> ; <i>Vglut2<sup>flx/flx</sup></i> )      | 194        |
| 5.        | Pharmacologically-induced dystonia models                                                       | 194        |
| 5.1       | Kainic acid injection (AMPA receptor activation)                                                | 195        |
| 5.2       | Ouabain injection (ATP1A3 sodium/potassium pump inhibition)                                     | 196        |
| 6.        | Other models of induced dystonia                                                                | 198        |
| 7.        | Conclusions                                                                                     | 198        |
|           | References                                                                                      | 201        |
| <b>7.</b> | <b>Advances in targeting neurotransmitter systems in dystonia</b>                               | <b>217</b> |
|           | Dora Steel, Kimberley M. Reid, Antonio Pisani, Ellen J. Hess,<br>Susan Fox, and Manju A. Kurian |            |
| 1.        | Introduction                                                                                    | 218        |
| 1.1       | A brief overview of dystonia                                                                    | 219        |
| 1.2       | The spectrum of brain neurotransmitters                                                         | 221        |
| 2.        | Physiology of the principal brain neurotransmitters                                             | 223        |
| 2.1       | Dopamine                                                                                        | 223        |
| 2.2       | Noradrenaline                                                                                   | 225        |
| 2.3       | Serotonin (5-hydroxytryptamine)                                                                 | 226        |
| 2.4       | Acetylcholine                                                                                   | 226        |
| 2.5       | GABA                                                                                            | 228        |
| 2.6       | Glutamate                                                                                       | 229        |

|                                                                                            |            |
|--------------------------------------------------------------------------------------------|------------|
| 2.7 Adenosine                                                                              | 230        |
| 2.8 Cannabinoids                                                                           | 231        |
| 3. Neurotransmitter-targeting pharmacological therapies                                    | 231        |
| 3.1 Dopamine                                                                               | 231        |
| 3.2 Noradrenaline                                                                          | 234        |
| 3.3 Serotonin (5-hydroxytryptamine)                                                        | 234        |
| 3.4 Acetylcholine                                                                          | 235        |
| 3.5 GABA                                                                                   | 236        |
| 3.6 Glutamate                                                                              | 237        |
| 3.7 Adenosine                                                                              | 238        |
| 3.8 Cannabinoids                                                                           | 240        |
| 4. New evolving genetic therapies targeting neurotransmitter systems                       | 241        |
| 4.1 Gene replacement strategies                                                            | 241        |
| 4.2 Gene editing                                                                           | 244        |
| 4.3 RNA therapies                                                                          | 244        |
| 5. Discussion                                                                              | 246        |
| Acknowledgements                                                                           | 248        |
| References                                                                                 | 248        |
| <br>                                                                                       |            |
| <b>8. Experimental pharmacology: Targeting metabolic pathways</b>                          | <b>259</b> |
| Vincenzo Leuzzi and Serena Galosi                                                          |            |
| 1. Introduction                                                                            | 260        |
| 2. Genetic-metabolic conditions causing dystonia with available disease-specific treatment | 270        |
| 3. Trace element metabolism disorders and NBIA disorders                                   | 271        |
| 3.1 Wilson disease                                                                         | 271        |
| 4. Manganese transport disorders                                                           | 273        |
| 5. Aceruloplasminemia                                                                      | 275        |
| 6. PKAN                                                                                    | 277        |
| 7. Energetic metabolism alterations                                                        | 280        |
| 8. Lysosomal disorders                                                                     | 287        |
| 9. Neurotransmitter defects                                                                | 293        |
| 10. Channelopathies and synaptopathies                                                     | 300        |
| 11. Conclusive remarks                                                                     | 301        |
| References                                                                                 | 302        |

|                                                                                                                                 |                |
|---------------------------------------------------------------------------------------------------------------------------------|----------------|
| <b>9. Adult-onset focal dystonias: To lump or split</b>                                                                         | <b>317</b>     |
| H. A. Jinnah and Giovanni DeFazio                                                                                               |                |
| 1. Introduction                                                                                                                 | 318            |
| 2. Lumping                                                                                                                      | 318            |
| 2.1 Shared evolution                                                                                                            | 318            |
| 2.2 Shared genetics                                                                                                             | 319            |
| 2.3 Shared physiology                                                                                                           | 319            |
| 2.4 Shared neuroanatomical basis                                                                                                | 320            |
| 2.5 Shared treatments                                                                                                           | 320            |
| 3. Splitting                                                                                                                    | 321            |
| 3.1 Clinical heterogeneity                                                                                                      | 321            |
| 3.2 Genetic heterogeneity                                                                                                       | 321            |
| 3.3 Anatomical heterogeneity                                                                                                    | 322            |
| 3.4 Physiological heterogeneity                                                                                                 | 322            |
| 3.5 Therapeutic heterogeneity                                                                                                   | 322            |
| 4. Resolving the paradox                                                                                                        | 323            |
| 5. Conclusions and future prospects                                                                                             | 324            |
| References                                                                                                                      | 325            |
| <br><b>10. Early-onset inherited dystonias versus late-onset idiopathic dystonias: Same or different biological mechanisms?</b> | <br><b>329</b> |
| Roberto Erro, Edoardo Monfrini, and Alessio Di Fonzo                                                                            |                |
| 1. Introduction                                                                                                                 | 330            |
| 2. Epidemiology, genetics and age at onset of dystonias                                                                         | 331            |
| 3. Age-related modifiers of genetic dystonias                                                                                   | 332            |
| 4. Converging biochemical and physiologic abnormalities                                                                         | 334            |
| 5. Critical periods of vulnerability for the sensorimotor system: Does it apply to dystonia?                                    | 337            |
| 6. A possible common framework: The double-hit hypothesis                                                                       | 339            |
| Disclosures                                                                                                                     | 341            |
| References                                                                                                                      | 341            |
| <br><b>11. Dystonia and Parkinson's disease: Do they have a shared biology?</b>                                                 | <br><b>347</b> |
| Elie Matar and Kailash Bhatia                                                                                                   |                |
| 1. Introduction                                                                                                                 | 348            |
| 2. Pathophysiological considerations—Convergence and divergence                                                                 | 348            |

|     |                                                            |     |
|-----|------------------------------------------------------------|-----|
| 2.1 | Anatomy of the basal ganglia                               | 349 |
| 2.2 | The direct, indirect, and hyper-direct pathways            | 352 |
| 2.3 | Matrix and striosome compartments                          | 354 |
| 2.4 | Cholinergic signaling in the striatum                      | 355 |
| 2.5 | Motor networks and cerebellum                              | 356 |
| 2.6 | Oscillatory activity in motor control                      | 359 |
| 3.  | Dystonia and Parkinson's disease                           | 360 |
| 3.1 | Pathology underlying motor symptoms of Parkinson's disease | 360 |
| 3.2 | Dystonia in pre-clinical and early PD                      | 362 |
| 3.3 | Treatment-associated dystonia/dyskinesia                   | 364 |
| 3.4 | Dystonia in monogenic PD                                   | 368 |
| 4.  | Dystonia and parkinsonism—Beyond PD                        | 372 |
| 4.1 | Drug-induced dystonia-parkinsonism                         | 377 |
| 4.2 | Dopamine synthesis and transport disorders                 | 378 |
| 4.3 | Disorders of brain iron accumulation and metal metabolism  | 382 |
| 4.4 | Neurodegenerative atypical parkinsonian disorders          | 386 |
| 5.  | Conclusion and future directions—One pathway or many?      | 390 |
|     | References                                                 | 392 |

## **12. Dystonia and tremor: Do they have a shared biology? 413**

**Abhishek Lenka and Sanjay Pandey**

|     |                                                               |     |
|-----|---------------------------------------------------------------|-----|
| 1.  | Introduction                                                  | 414 |
| 2.  | Evidence in favor of shared biology                           | 415 |
| 2.1 | Evidence from the clinical and epidemiological studies        | 415 |
| 2.2 | Evidence from the genetic studies                             | 424 |
| 2.3 | Evidence from the neuroimaging studies                        | 426 |
| 2.4 | Evidence from postmortem histopathology studies               | 428 |
| 2.5 | Evidence from neurophysiology studies                         | 428 |
| 3.  | Evidence against a shared biology                             | 429 |
| 3.1 | The pathophysiology of subtypes of tremor is likely different | 429 |
| 3.2 | Genetic and anatomical overlaps are unclear                   | 430 |
| 3.3 | Therapeutic responses are inconsistent                        | 431 |
|     | Conclusion and future perspectives                            | 431 |
|     | Funding source                                                | 432 |
|     | Conflicts of interest                                         | 432 |
|     | References                                                    | 432 |

|                                                                                                              |                |
|--------------------------------------------------------------------------------------------------------------|----------------|
| <b>13. How does botulinum toxin really work?</b>                                                             | <b>441</b>     |
| Daniele Belvisi, Giorgio Leodori, Matteo Costanzo,<br>Antonella Conte, and Alfredo Berardelli                |                |
| 1. Background                                                                                                | 442            |
| 1.1 What is the evidence that the primary mechanism is inhibition of<br>neuromuscular junction transmission? | 443            |
| 1.2 What is the evidence for alteration of peripheral sensory<br>feedback from muscle spindles?              | 453            |
| 2. What is the evidence for a central effect?                                                                | 458            |
| 2.1 Evidence of retrograde and anterograde BoNT transportation in<br>animal models                           | 458            |
| 3. Neurophysiological evidence of BoNT effects on brainstem excitability<br>in humans                        | 459            |
| 3.1 Neurophysiological evidence of BoNT effects on motor cortex<br>excitability in humans                    | 464            |
| 4. Neurophysiological evidence of BoNT effects on the sensory system<br>in humans                            | 466            |
| 5. Neuroimaging evidence of central effects of BoNT in humans                                                | 468            |
| 6. Conclusions                                                                                               | 470            |
| References                                                                                                   | 471            |
| <br><b>14. What have we learned about the biology of dystonia<br/>    from deep brain stimulation?</b>       | <br><b>481</b> |
| Vidailhet Marie                                                                                              |                |
| References                                                                                                   | 488            |